In the realm of toxicology, idarucizumab plays a pivotal role in managing dabigatran-associated bleeding events. As the use of DOACs has increased, the need for effective reversal agents has become more pressing. Idarucizumab addresses this need by offering a targeted approach to mitigate the risks associated with dabigatran toxicity, particularly in overdose cases or when interactions with other drugs increase bleeding risk.
